GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Debt-to-Asset

Oncodesign Precision Medicine (XPAR:ALOPM) Debt-to-Asset : 0.57 (As of Jun. 2022)


View and export this data going back to 2022. Start your Free Trial

What is Oncodesign Precision Medicine Debt-to-Asset?

Oncodesign Precision Medicine's Short-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was €0.00 Mil. Oncodesign Precision Medicine's Long-Term Debt & Capital Lease Obligation for the quarter that ended in Jun. 2022 was €2.68 Mil. Oncodesign Precision Medicine's Long-Term Debt & Capital Lease ObligationTotal Assets for the quarter that ended in Jun. 2022 was €4.72 Mil. Oncodesign Precision Medicine's debt to asset for the quarter that ended in Jun. 2022 was 0.57.

Oncodesign Precision Medicine Debt-to-Asset Historical Data

The historical data trend for Oncodesign Precision Medicine's Debt-to-Asset can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Oncodesign Precision Medicine Debt-to-Asset Chart

Oncodesign Precision Medicine Annual Data
Trend Dec20 Dec21
Debt-to-Asset
0.25 0.35

Oncodesign Precision Medicine Semi-Annual Data
Dec20 Dec21 Jun22
Debt-to-Asset 0.25 0.35 0.57

Competitive Comparison of Oncodesign Precision Medicine's Debt-to-Asset

For the Biotechnology subindustry, Oncodesign Precision Medicine's Debt-to-Asset, along with its competitors' market caps and Debt-to-Asset data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Oncodesign Precision Medicine's Debt-to-Asset Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Oncodesign Precision Medicine's Debt-to-Asset distribution charts can be found below:

* The bar in red indicates where Oncodesign Precision Medicine's Debt-to-Asset falls into.


Oncodesign Precision Medicine Debt-to-Asset Calculation

Debt to Asset measures the financial leverage a company has.

Oncodesign Precision Medicine's Debt-to-Asset for the fiscal year that ended in Dec. 2021 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 2.907) / 8.372
=0.35

Oncodesign Precision Medicine's Debt-to-Asset for the quarter that ended in Jun. 2022 is calculated as

Debt-to-Asset=Total Debt / Total Assets
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Assets
=(0 + 2.684) / 4.722
=0.57

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Oncodesign Precision Medicine  (XPAR:ALOPM) Debt-to-Asset Explanation

In the calculation of Debt-to-Asset, we use the total of Short-Term Debt & Capital Lease Obligation and Long-Term Debt & Capital Lease Obligation divided by Total Assets.

Oncodesign Precision Medicine Debt-to-Asset Related Terms

Thank you for viewing the detailed overview of Oncodesign Precision Medicine's Debt-to-Asset provided by GuruFocus.com. Please click on the following links to see related term pages.

Oncodesign Precision Medicine (XPAR:ALOPM) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Oncodesign Precision Medicine SA (XPAR:ALOPM) » Definitions » Debt-to-Asset
Comparable Companies
Traded in Other Exchanges
N/A
Address
18 rue Jean Mazen, Dijon, FRA, 21000
Website
https://www.opm.oncodesign.com
Oncodesign Precision Medicine SA is a biopharmaceutical company specialised in precision medicine. Its mission is to provide patients with effective diagnostic and therapeutic solutions for resistant and metastatic cancers.

Oncodesign Precision Medicine (XPAR:ALOPM) Headlines

No Headlines